ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF

• US 20170121420A1
• Filed: 11/01/2016
• Published: 05/04/2017
• Est. Priority Date: 11/02/2015
• Status: Abandoned Application

• Current Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Original Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Inventors: Dinh, Thai, Cardoso, Rosa Maria Fernandes, Gaudet, Francois, Heidrich, Bradley J., Nemeth, Jennifer F., Nishioka, Jr., Walter K., Pizutti, Darlene, Strake, Brandy, Fisher, Jamie, Attar, Ricardo Marcos, Salvati, Mark E.
• Application Number:
  US15/340,149
• Publication Number:
  US 20170121420A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: C07K 16/3023 Lung
• CPC Class Codes: C07K 16/303 Liver or Pancreas
• CPC Class Codes: C07K 16/3038 Kidney, bladder
• CPC Class Codes: C07K 16/3046 Stomach, Intestines
• CPC Class Codes: C07K 16/3053 Skin, nerves, brain
• CPC Class Codes: C07K 16/3061 Blood cells
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 : multispecific
• CPC Class Codes: C07K 2317/33 : Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 : Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/51 : Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/515 : Complete light chain, i.e. VL + CL
• CPC Class Codes: C07K 2317/55 : Fab or Fab'
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/73 : Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multispecific antibodies against IL1RAP and CD3 described herein.

Claims

1. An isolated antibody, or an antigen-binding fragment thereof, that binds specifically to IL1RAP comprising:

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

68 and a light chain sequence set forth in SEQ ID NO;

69;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

70 and a light chain sequence set forth in SEQ ID NO;

71;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

72 and a light chain sequence set forth in SEQ ID NO;

73;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

74 and a light chain sequence set forth in SEQ ID NO;

75;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

76 and a light chain sequence set forth in SEQ ID NO;

77;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

78 and a light chain sequence set forth in SEQ ID NO;

79;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

80 and a light chain sequence set forth in SEQ ID NO;

79;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

81 and a light chain sequence set forth in SEQ ID NO;

82;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

83 and a light chain sequence set forth in SEQ ID NO;

84;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

85 and a light chain sequence set forth in SEQ ID NO;

84;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

86 and a light chain sequence set forth in SEQ ID NO;

84;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

74 and a light chain sequence set forth in SEQ ID NO;

87;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

76 and a light chain sequence set forth in SEQ ID NO;

88;

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

76 and a light chain sequence set forth in SEQ ID NO;

89;

or

an antibody comprising a heavy chain sequence set forth in SEQ ID NO;

90 and a light chain sequence set forth in SEQ ID NO;

91.

2. The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment thereof binds to the extracellular domain of human IL1RAP.

3. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment is a human antibody or antigen-binding fragment.

4. The antibody or antigen-binding fragment of claim 1 having an IgG1 or IgG4 isotype.

5. The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds human IL1RAP and cross reacts with cynomolgus monkey IL1RAP.

6. An isolated cell expressing the antibody or antigen-binding fragment of claim 1.

7. The cell of claim 6 wherein the antibody is recombinantly produced.

8. An isolated IL1RAP×

CD3 bispecific antibody comprising;

a) a first heavy chain (HC1);

b) a second heavy chain (HC2);

c) a first light chain (LC1); and

d) a second light chain (LC2),

wherein the HC1 and the LC1 pair to form a first antigen-binding site that specifically binds CD3, and the HC2 and the LC2 pair to form a second antigen-binding site that specifically binds IL1RAP, or an IL1RAP×

CD3 bispecific binding fragment thereof.

9. The IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 8, wherein HC1 comprises SEQ ID NO;

94 LC1 comprises SEQ ID NO;

95, HC2 comprises SEQ ID NO;

72, and LC2 comprises SEQ ID NO;

73.

10. The IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 8, wherein the antibody or bispecific binding fragment specifically binds IL1RAP with a KD of less than about 30 nM as measured by surface plasmon resonance.

11. The IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 8, wherein the antibody or bispecific binding fragment thereof binds IL1RAP on the surface of cells selected from the group consisting of human acute myeloid leukemia cells, human lung cancer cells, human colon cancer cells, human pancreatic cancer cells, human myelodysplastic syndrome cancer cells, human chronic myeloid leukemia, human diffuse large B-Cell lymphoma cells, human acute lymphoblastic leukemia cells, and human T-cell leukemia/lymphoma cells.

12. The IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 8, wherein the antibody or bispecific binding fragment inhibits IL-1β

mediated signaling through AP-1 and NF-κ

B responsive elements at concentrations above 6.7 nM.

13. The IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 8, wherein the antibody or bispecific binding fragment induces T-cell dependent cytotoxicity of IL1RAP-expressing cells in vitro with an EC50 of less than about 1.3 nM.

14. An isolated IL1RAP×

CD3 bispecific antibody or an IL1RAP×

CD3 bispecific binding fragment thereof comprising;

a) a first heavy chain (HC1);

b) a second heavy chain (HC2);

c) a first light chain (LC1); and

d) a second light chain (LC2),

wherein the HC1 and the LC1 pair to form a first antigen-binding site that specifically binds CD3 and comprise a heavy chain CDR1 (HCDR1) as depicted in SEQ ID NO;

96, an HCDR2 as depicted in SEQ ID NO;

102, an HCDR3 as depicted in SEQ ID NO;

98 a light chain CDR1 (LCDR1) as depicted in SEQ ID NO;

99, an LCDR2 as depicted in SEQ ID NO;

100, and an LCDR3 as depicted in SEQ ID NO;

101;

and the HC2 and the LC2 pair to form a second antigen-binding site that specifically binds IL1RAP and comprise a heavy chain CDR1 (HCDR1) as depicted in SEQ ID NO;

16 or 22, an HCDR2 as depicted in SEQ ID NO;

17 or 23, an HCDR3 as depicted in SEQ ID NO;

18 or 24 a light chain CDR1 (LCDR1) as depicted in SEQ ID NO;

46 or 62, an LCDR2 as depicted in SEQ ID NO;

47 or 63, and an LCDR3 as depicted in SEQ ID NO;

103 or 64.

15. An isolated cell expressing the antibody or bispecific binding fragment of claim 14.

16. The cell of claim 15 wherein the antibody or bispecific binding fragment is recombinantly produced.

17. A method for treating a subject having cancer, said method comprising:

administering a therapeutically effective amount of the IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14 to a patient in need thereof for a time sufficient to treat the cancer.

18. A method for inhibiting growth or proliferation of cancer cells, said method comprising:

administering a therapeutically effective amount of the IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14 to inhibit the growth or proliferation of cancer cells.

19. A method of redirecting a T cell to an IL1RAP-expressing cancer cell, said method comprising:

administering a therapeutically effective amount of the IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14 to redirect a T cell to a cancer.

20. The method of claim 19 wherein the cancer is an IL1RAP-expressing cancer.

21. The method of claim 20 wherein the IL1RAP-expressing cancer, is acute myeloid leukemia (AML) myelodysplastic syndrome (MDS, low or high risk), acute lymphocytic leukemia (ALL, including all subtypes), diffuse large B-cell lymphoma (DLBCL), chronic myeloid leukemia (CML), blastic plasmacytoid dendritic cell neoplasm (DPDCN), T-cell leukemia/lymphoma, prostate cancer, lung cancer, colorectal cancer, or pancreatic cancer.

22. The method of claim 19 further comprising administering a second therapeutic agent.

23. The method of claim 22 wherein the second therapeutic agent is a chemotherapeutic agent or a targeted anti-cancer therapy.

24. The method of claim 23 wherein the chemotherapeutic agent is cytarabine, an anthracycline, histamine dihydrochloride, or interleukin 2.

25. The method of claim 22 wherein the second therapeutic agent is administered to said subject simultaneously with, sequentially, or separately from the bispecific antibody.

26. A pharmaceutical composition comprising the IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14 and a pharmaceutically acceptable carrier.

27. An isolated synthetic polynucleotide encoding the HC1, the HC2, the LC1 or the LC2 of the IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14.

28. A kit comprising the IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14 and instructions for use thereof.

29. A method of inhibiting angiogenesis in a subject, said method comprising administering to a subject in need thereof a IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14, wherein the subject has cancer.

30. A method of depleting MDSCs in a subject, said method comprising administering to a subject in need thereof a IL1RAP×

CD3 bispecific antibody or bispecific binding fragment of claim 14, wherein the subject has cancer.